ArticleCureus2025
Raising Suspicion of Thrombotic Thrombocytopenic Purpura in a Patient With a Pre-existing Autoimmune Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a rare form of microangiopathic hemolytic anemia with high rates of mortality without treatment. Common risk factors for TTP include immunosuppression, pregnancy, and female gender. However, several case reports show that TTP may have an association with autoimmune conditions such as Sjögren's syndrome (SS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). We present a similar case of a 41-year-old female with a past medical history of RA, SLE, and SS, who arrived at the hospital with hematuria, flank pain, slow speech, and altered mental status. Based on her presentation, there were concerns for TTP, hemolytic uremic syndrome, glomerulonephritis, or sepsis secondary to urinary tract infection. After diagnosis was narrowed to TTP, treatment was initiated for TTP with plasmapheresis, methylprednisolone, and rituximab infusions prior to receiving diagnostic confirmation due to high clinical suspicion. Upon further workup, her autoimmune and immunology panels returned several days post-admission with low ADAMTS13 activity, confirming the TTP diagnosis. Her autoimmune conditions were also confirmed for SS, RA, and SLE based on positive serology for anti-SSA/Ro antibodies, anti-CCP antibodies, and speckled ANA, respectively. With treatment, the platelet counts increased, and the symptoms present at admission resolved over a prolonged hospital course. Initiating treatment for TTP should be based on findings of clinical and routine laboratory testing rather than confirmatory test results due to the delay in receiving results, such as the ADAMTS13 level. In patients with a history of autoimmune disease, the association between TTP and autoimmune diseases can help formulate a clinical diagnosis of TTP early in the hospital course, allowing for treatment initiation and decreased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.